Autolus Therapeutics plc (AUTL) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth No data; EPS growth Lose.
15/46
1.6 / 5 stars
All 46 Win/Lose results and 74 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 6 wins, 5 losses, 1 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinAUTL / S&P 15.94% / 15.20% |
WinAUTL / S&P 292.16% / 15.00% |
LoseAUTL / S&P 26.19% / 50.40% |
| 2026-Q11/3 |
LoseAUTL / S&P -30.65% / -4.33% |
WinAUTL / S&P 927.90% / 11.30% |
LoseAUTL / S&P 23.86% / 27.70% |
| 2025-Q43/3 |
WinAUTL / S&P 22.09% / 2.65% |
WinAUTL / S&P 644.94% / 9.00% |
WinAUTL / S&P 25.58% / 13.40% |
| 2025-Q30/2 |
LoseAUTL / S&P -28.51% / 8.12% |
No dataAUTL / S&P / 4.61% |
LoseAUTL / S&P -31.97% / 13.45% |
| 2025-Q21/2 |
WinAUTL / S&P 47.10% / 10.94% |
No dataAUTL / S&P / 4.83% |
LoseAUTL / S&P -28.21% / 10.63% |
| 2025-Q10/2 |
LoseAUTL / S&P -34.04% / -4.27% |
No dataAUTL / S&P / 4.98% |
LoseAUTL / S&P -27.27% / 10.57% |
| 2024-Q40/2 |
LoseAUTL / S&P -35.26% / 2.41% |
No dataAUTL / S&P / 5.25% |
LoseAUTL / S&P -28.33% / 6.15% |
| 2024-Q31/2 |
LoseAUTL / S&P 4.31% / 5.89% |
No dataAUTL / S&P / 5.89% |
WinAUTL / S&P 24.49% / 6.11% |
| 2024-Q20/2 |
LoseAUTL / S&P -45.45% / 4.28% |
No dataAUTL / S&P / 5.38% |
LoseAUTL / S&P -1.68% / 5.12% |
| 2024-Q10/1 |
LoseAUTL / S&P -0.93% / 10.56% |
No dataAUTL / S&P / 5.71% |
No dataAUTL / S&P / 5.59% |
| 2023-Q41/1 |
WinAUTL / S&P 176.39% / 11.69% |
No dataAUTL / S&P / 6.81% |
No dataAUTL / S&P / 7.78% |
| 2023-Q31/1 |
WinAUTL / S&P -2.10% / -3.27% |
No dataAUTL / S&P / 7.52% |
No dataAUTL / S&P / -5.03% |
| 2023-Q21/1 |
WinAUTL / S&P 29.35% / 8.74% |
No dataAUTL / S&P / 9.50% |
No dataAUTL / S&P / -8.57% |
| 2023-Q10/1 |
LoseAUTL / S&P -3.16% / 7.50% |
No dataAUTL / S&P / 10.77% |
No dataAUTL / S&P / -15.69% |
| 2022-Q40/1 |
LoseAUTL / S&P -11.21% / 7.56% |
No dataAUTL / S&P / 11.88% |
No dataAUTL / S&P / -17.99% |
| 2022-Q30/1 |
LoseAUTL / S&P -24.38% / -4.88% |
No dataAUTL / S&P / 13.47% |
No dataAUTL / S&P / -1.41% |
| 2022-Q20/1 |
LoseAUTL / S&P -32.13% / -16.10% |
No dataAUTL / S&P / 13.71% |
No dataAUTL / S&P / 11.04% |
| 2022-Q10/1 |
LoseAUTL / S&P -19.65% / -4.60% |
No dataAUTL / S&P / 15.97% |
No dataAUTL / S&P / 42.23% |
| 2021-Q40/1 |
LoseAUTL / S&P -20.76% / 11.03% |
No dataAUTL / S&P / 15.00% |
No dataAUTL / S&P / 96.40% |
| 2021-Q30/1 |
LoseAUTL / S&P -1.36% / 0.58% |
No dataAUTL / S&P / 10.77% |
No dataAUTL / S&P / 69.42% |
| 2021-Q21/1 |
WinAUTL / S&P 15.88% / 8.55% |
No dataAUTL / S&P / 6.58% |
No dataAUTL / S&P / 51.81% |
| 2021-Q10/1 |
LoseAUTL / S&P -35.91% / 6.17% |
No dataAUTL / S&P / -1.06% |
No dataAUTL / S&P / 7.39% |
| 2020-Q40/1 |
LoseAUTL / S&P -23.20% / 12.15% |
No dataAUTL / S&P / -3.72% |
No dataAUTL / S&P / -33.42% |
| 2020-Q30/1 |
LoseAUTL / S&P -27.39% / 8.93% |
No dataAUTL / S&P / -2.04% |
No dataAUTL / S&P / -27.10% |
| 2020-Q21/2 |
WinAUTL / S&P 167.61% / 20.54% |
LoseAUTL / S&P -57.42% / -0.46% |
No dataAUTL / S&P / -27.11% |
| 2020-Q10/2 |
LoseAUTL / S&P -54.62% / -19.60% |
LoseAUTL / S&P -57.41% / 3.47% |
No dataAUTL / S&P / -14.75% |
| 2019-Q40/1 |
LoseAUTL / S&P 6.28% / 9.07% |
No dataAUTL / S&P / 5.36% |
No dataAUTL / S&P / 2.99% |
| 2019-Q30/1 |
LoseAUTL / S&P -22.86% / 1.70% |
No dataAUTL / S&P / 5.02% |
No dataAUTL / S&P / 0.21% |
| 2019-Q20/1 |
LoseAUTL / S&P -48.84% / 4.30% |
No dataAUTL / S&P / 6.64% |
No dataAUTL / S&P / 8.65% |
| 2019-Q10/1 |
LoseAUTL / S&P -4.17% / 13.65% |
No dataAUTL / S&P / 8.12% |
No dataAUTL / S&P / 14.29% |
| 2018-Q41/1 |
WinAUTL / S&P 7.08% / -13.52% |
No dataAUTL / S&P / 9.05% |
No dataAUTL / S&P / 18.23% |
| 2018-Q31/1 |
WinAUTL / S&P 14.48% / 7.71% |
No dataAUTL / S&P / 10.21% |
No dataAUTL / S&P / 19.06% |
| 2018-Q20/0 |
No dataAUTL / S&P / 3.43% |
No dataAUTL / S&P / 9.03% |
No dataAUTL / S&P / 14.46% |
| 2018-Q10/0 |
No dataAUTL / S&P / -0.76% |
No dataAUTL / S&P / 7.68% |
No dataAUTL / S&P / 12.46% |
| 2017-Q40/0 |
No dataAUTL / S&P / 6.64% |
No dataAUTL / S&P / 7.03% |
No dataAUTL / S&P / 13.82% |
| 2017-Q30/0 |
No dataAUTL / S&P / 4.48% |
No dataAUTL / S&P / 5.68% |
No dataAUTL / S&P / 17.57% |
| 2017-Q20/0 |
No dataAUTL / S&P / 3.09% |
No dataAUTL / S&P / 4.83% |
No dataAUTL / S&P / 17.74% |
| 2017-Q10/0 |
No dataAUTL / S&P / 6.07% |
No dataAUTL / S&P / 3.67% |
No dataAUTL / S&P / 13.32% |
| 2016-Q40/0 |
No dataAUTL / S&P / 3.82% |
No dataAUTL / S&P / 2.09% |
No dataAUTL / S&P / 7.05% |
| 2016-Q30/0 |
No dataAUTL / S&P / 3.85% |
No dataAUTL / S&P / 0.20% |
No dataAUTL / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AUTL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 57.33% | 20.78% |
| Annualized return | 57.33% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AUTL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -66.99% | 83.14% |
| Annualized return | -19.88% | 12.86% |
10Y · 2018-06-22 to 2026-08-27
| Metric | AUTL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -90.56% | 319.30% |
| Annualized return | -21.02% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |